##gff-version 3								
##gvf-version 1.10								
##species NCBI_Taxonomy_URI=http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
MN908947.3	.	snp	241	241	.	+	.	ID=ID_0;Name=c.C-25T;chrom_region=5' UTR;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C-25T;aa_name=;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	1473	1473	.	+	.	ID=ID_1;Name=p.T403I;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725298.1;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C1208T;aa_name=p.T403I;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	2067	2067	.	+	.	ID=ID_2;Name=p.I601T;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725298.1;ro=2;ao=2;dp=4;Reference_seq=T;Variant_seq=C;nt_name=c.T1802C;aa_name=p.I601T;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	3037	3037	.	+	.	ID=ID_3;Name=p.F924F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C2772T;aa_name=p.F924F;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	6236	6236	.	+	.	ID=ID_4;Name=p.V1991I;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G5971A;aa_name=p.V1991I;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	10323	10323	.	+	.	ID=ID_5;Name=p.K3353R;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=3C-like proteinase;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725301.1;ro=2;ao=2;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A10058G;aa_name=p.K3353R;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_6;Name=p.S3675del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=4;dp=4;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.620;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='3676del', 'F3677del';sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	14408	14408	.	+	.	ID=ID_7;Name=p.P4715L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C14144T;aa_name=p.P4715L;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_6;Name=p.3676del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=4;dp=4;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.620;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', 'F3677del';sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_6;Name=p.F3677del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=4;dp=4;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.620;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', '3676del';sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_6;Name=p.3676del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=4;dp=4;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.620;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', 'F3677del';sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	14408	14408	.	+	.	ID=ID_7;Name=p.P4715L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C14144T;aa_name=p.P4715L;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	14931	14931	.	+	.	ID=ID_8;Name=p.N4889N;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=3;ao=1;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C14667T;aa_name=p.N4889N;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	15324	15324	.	+	.	ID=ID_9;Name=p.N5020N;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C15060T;aa_name=p.N5020N;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	17110	17110	.	+	.	ID=ID_10;Name=p.A5616S;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=helicase;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_acc=YP_009725308.1;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=T;nt_name=c.G16846T;aa_name=p.A5616S;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	17746	17746	.	+	.	ID=ID_11;Name=p.P5828S;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=helicase;mat_pep_desc=nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only;mat_pep_acc=YP_009725308.1;ro=2;ao=2;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C17482T;aa_name=p.P5828S;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	20049	20049	.	+	.	ID=ID_12;Name=p.I6595I;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=endoRNAse;mat_pep_desc=nsp15-A1 and nsp15B-NendoU, produced by pp1ab only;mat_pep_acc=YP_009725310.1;ro=0;ao=4;dp=4;Reference_seq=T;Variant_seq=C;nt_name=c.T19785C;aa_name=p.I6595I;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	21575	21575	.	+	.	ID=ID_13;Name=p.L5F;chrom_region=S;ps_filter=mask;ps_exc=highly_homoplasic;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=3;ao=1;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C13T;aa_name=p.L5F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	21575	21575	.	+	.	ID=ID_13;Name=p.L5F;chrom_region=S;ps_filter=mask;ps_exc=highly_homoplasic;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=3;ao=1;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C13T;aa_name=p.L5F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	21575	21575	.	+	.	ID=ID_13;Name=p.L5F;chrom_region=S;ps_filter=mask;ps_exc=highly_homoplasic;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=3;ao=1;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C13T;aa_name=p.L5F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	21638	21638	.	+	.	ID=ID_14;Name=p.P26S;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C76T;aa_name=p.P26S;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	21638	21638	.	+	.	ID=ID_14;Name=p.P26S;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C76T;aa_name=p.P26S;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	21638	21638	.	+	.	ID=ID_14;Name=p.P26S;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C76T;aa_name=p.P26S;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_15;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';sample_size=4;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_16;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation='V70del';function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	"ID=ID_17;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_16;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='V70del';function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_16;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='V70del';function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_15;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';sample_size=4;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_17;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_17;Name=p.H69del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='V70del';sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'V70del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	21939	21939	.	+	.	ID=ID_18;Name=p.V126A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=T;Variant_seq=C;nt_name=c.T377C;aa_name=p.V126A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_15;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';sample_size=4;function_category=immunosuppression variant emergence;source=https://doi.org/10.1101/2020.12.14.422555;citation=Kemp et al. (2020);comb_mutation=;function_description=The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_19;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation='H69del';function_description=Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	"ID=ID_20;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_19;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='H69del';function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_19;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation='H69del';function_description=Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_15;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';sample_size=4;function_category=convalescent plasma escape;source=https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1;citation=Kemp et al. (2020);comb_mutation=;function_description=Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_20;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21764	21764	.	+	.	ID=ID_20;Name=p.V70del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ATACATG;Variant_seq=A;nt_name=c.203_208delTACATG;aa_name=p.H69_V70del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=H69_V70del;multiaa_comb_mutation='H69del';sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G', 'H69del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	21939	21939	.	+	.	ID=ID_18;Name=p.V126A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=T;Variant_seq=C;nt_name=c.T377C;aa_name=p.V126A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_21;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=immunosuppression variant emergence;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640888/;citation=Avanzato et al. (2020);comb_mutation=;function_description=Emergent as 100% variant from larger minor (1% allele frequency) deletion by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia. Variant disappeared after convalescent plasma treatment (day 71) in subsequent sample sequencing.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_21;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 1% to 0.17% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: N501Y, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21990	21990	.	+	.	"ID=ID_21;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Massive reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition) ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_21;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Abolishes neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_22;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_21;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_21;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abf6950;citation=McCarthy et al. (2021);comb_mutation=;function_description=Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 4 patients.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_22;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	21990	21990	.	+	.	ID=ID_22;Name=p.Y144del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=TTTA;Variant_seq=T;nt_name=c.429_431delTTA;aa_name=p.Y144del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L241del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L242del', 'A243del';sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22295	22295	.	+	.	ID=ID_24;Name=p.H245Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C733T;aa_name=p.H245Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation=;function_description=Ablates binding of Spike N terminal domain targeting monoclonal antibody 4A8, by disruption of N5-loop/supersite loop, may work synergistically with  501Y.V2 (""South African"") lineage background variant R246I to disrupt paratope binding. [PG: del extent simplified to accomodate minor position realignments];heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, 2-17, and 4-19 (independent of S:p.R246I).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  deletion does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abf6950;citation=McCarthy et al. (2021);comb_mutation=;function_description=Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_23;Name=p.A243del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'L242del';sample_size=4;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.A243del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'L242del';sample_size=4;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation=;function_description=Ablates binding of Spike N terminal domain targeting monoclonal antibody 4A8, by disruption of N5-loop/supersite loop, may work synergistically with  501Y.V2 (""South African"") lineage background variant R246I to disrupt paratope binding. [PG: del extent simplified to accomodate minor position realignments];heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, 2-17, and 4-19 (independent of S:p.R246I).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  deletion does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abf6950;citation=McCarthy et al. (2021);comb_mutation=;function_description=Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.620;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';sample_size=4;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22295	22295	.	+	.	ID=ID_24;Name=p.H245Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C733T;aa_name=p.H245Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22498	22498	.	+	.	ID=ID_25;Name=p.I312I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C936T;aa_name=p.I312I;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_26;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=symptom prevalence;source=https://doi.org/10.1016/j.ijid.2021.03.068;citation=Fournier et al. (2021);comb_mutation='D614G';function_description=Compared to the clade 20A strains that predominated during phase 1 between March and May 2020, the Marseille-4 variant (characterized  by this mutation plus N:p.M234I:A376T) was associated with a lower frequency of cough, rhinitis, and olfactory and gustatory disorders.  By contrast, hypoxemia was more frequent in patients infected with the Marseille-4 variant.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_27;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows some resistence across all antibodies tested.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_27;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_27;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_27;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=;comb_mutation=;function_description=Increased affinity for ACE2: clade in Australia 2020-05-27 onward, clade in Europe 2020-08-08 onward Modelling shows flexible region in Spike RBD with residue S477 having the greatest rotational flexibility.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_27;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding, with increasing proportion in subsequent rounds.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_26;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_28;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='E484K';function_description=Bamlanivimab (LY-CoV555) lost ~10x binding against this double mutation. Tixagevimab lost ~16x binding against this double mutation.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_26;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was neutralized slightly less than D614G in 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_27;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mixed bag of mild positive and negative changes in neutralization capability of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), 10 show low neutralization.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_27;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_27;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 host variant dependency;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=This mutation's measured interaction affinity with ACE2:p.S19P (0.03% minor allele frequency,  found almost exclusively in African/African-Americans in the GnomAD database) was significantly lower than the predicted value,  indicating that these mutations were not independent. This is consistent with the fact that the ACE2 residue S19  is adjacent to RBD residue S477 in the contact interface. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_27;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.06 fold;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	ID=ID_27;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.22 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	22992	22992	.	+	.	"ID=ID_26;Name=p.S477N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1430A;aa_name=p.S477N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=reinfection;source=https://doi.org/10.1016/j.ijid.2021.03.068;citation=Fournier et al. (2021);comb_mutation='D614G';function_description=11 cases of re-infection with the ""Marseille-4"" variant found within 1028 positive tests, where all of the earlier infections were from different strains. This lineage is also characterized by N:p.M234I:A376T;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1;citation=Li et al. (2021);comb_mutation=;function_description=Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus);heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_30;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd = 38.5nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_30;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_28;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='S477N';function_description=Bamlanivimab (LY-CoV555) lost ~10x binding against this double mutation. Tixagevimab lost ~16x binding against this double mutation.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_30;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees);heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	"ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	"ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	"ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.12.28.424451;citation=Andreano et al. (2020);comb_mutation=;function_description=This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_30;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_30;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1084/jem.20202756;citation=Solfrosi et al. (2021);comb_mutation=;function_description=Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation=;function_description=E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S2666-5247(21;citation=Jangra et al. (2021);comb_mutation=;function_description=Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_30;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=monoclonal antibody serial passage escape;source=http://dx.doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=;function_description=Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage);heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=monoclonal antibody serial passage escape;source=https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin=ppub;citation=Barnes et al. (2020);comb_mutation=;function_description=The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_30;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=symptom prevalence;source=https://doi.org/10.1016/j.ijid.2021.03.068;citation=Fournier et al. (2021);comb_mutation='S477N';function_description=Compared to the clade 20A strains that predominated during phase 1 between March and May 2020, the Marseille-4 variant (characterized  by this mutation plus N:p.M234I:A376T) was associated with a lower frequency of cough, rhinitis, and olfactory and gustatory disorders.  By contrast, hypoxemia was more frequent in patients infected with the Marseille-4 variant.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_32;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_22;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='Y144del';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_33;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P681H';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_34;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D1118H';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_14;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P26S';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_35;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='T1027I';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_13;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L5F';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='S477N';function_description=Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no significant change in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='E484K';function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation='S477N';function_description=Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage was neutralized slightly less than D614G in 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_32;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_22;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='Y144del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_33;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P681H';function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_34;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D1118H';function_description=1.96x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_14;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P26S';function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_35;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='T1027I';function_description=1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_13;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L5F';function_description=No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='E484K';function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_33;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1;citation=Zuckerman et al. (2021);comb_mutation='P681H';function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_31;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=reinfection;source=https://doi.org/10.1016/j.ijid.2021.03.068;citation=Fournier et al. (2021);comb_mutation='S477N';function_description=11 cases of re-infection with the ""Marseille-4"" variant found within 1028 positive tests, where all of the earlier infections were from different strains. This lineage is also characterized by N:p.M234I:A376T;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_32;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='H69del', 'V70del';function_description=1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_22;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='Y144del';function_description=1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_33;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P681H';function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_34;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D1118H';function_description=1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_30;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_14;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='P26S';function_description=1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_35;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='T1027I';function_description=1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_13;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L5F';function_description=1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23416	23416	.	+	.	ID=ID_36;Name=p.T618T;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=T;nt_name=c.A1854T;aa_name=p.T618T;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_37;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_37;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/ ;citation=Johnson et al. (2020);comb_mutation=;function_description=This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_37;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_33;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_37;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_37;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=Maaroufi (2021);comb_mutation=;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_37;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1;citation=Lubinski et al. (2021);comb_mutation=;function_description=While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_33;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_33;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1;citation=Zuckerman et al. (2021);comb_mutation='D614G';function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_37;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	23604	23604	.	+	.	ID=ID_33;Name=p.P681H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=A;nt_name=c.C2042A;aa_name=p.P681H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	24642	24642	.	+	.	ID=ID_35;Name=p.T1027I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C3080T;aa_name=p.T1027I;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	24642	24642	.	+	.	ID=ID_35;Name=p.T1027I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C3080T;aa_name=p.T1027I;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	24642	24642	.	+	.	ID=ID_38;Name=p.T1027I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C3080T;aa_name=p.T1027I;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 1.51 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	24642	24642	.	+	.	ID=ID_35;Name=p.T1027I;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C3080T;aa_name=p.T1027I;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	24914	24914	.	+	.	ID=ID_39;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Mutation is predicted to lose the T cell epitope for people carrying DRB1*0301 and DRB1*0401,  but not for example in those who are DRB1*0701 or DRB1*1501 who would be predicted to show an enhanced response. This is also observed in a study of 26 each post-infection and post first dose HCWs.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	24914	24914	.	+	.	ID=ID_39;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	24914	24914	.	+	.	"ID=ID_34;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;"
MN908947.3	.	snp	24914	24914	.	+	.	ID=ID_39;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, hence this individual variant  is unlikely to contribute to cell entry fitness. ;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	24914	24914	.	+	.	ID=ID_34;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.96x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	24914	24914	.	+	.	ID=ID_34;Name=p.D1118H;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=G;Variant_seq=C;nt_name=c.G3352C;aa_name=p.D1118H;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	25033	25033	.	+	.	ID=ID_40;Name=p.K1157K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=2;ao=2;dp=4;Reference_seq=G;Variant_seq=A;nt_name=c.G3471A;aa_name=p.K1157K;vcf_gene=S;mutation_type=SILENT;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	25563	25563	.	+	.	ID=ID_41;Name=p.Q57H;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=2;ao=2;dp=4;Reference_seq=G;Variant_seq=C;nt_name=c.G171C;aa_name=p.Q57H;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	25658	25658	.	+	.	ID=ID_42;Name=p.T89I;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=2;ao=2;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C266T;aa_name=p.T89I;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	25916	25916	.	+	.	ID=ID_43;Name=p.T175I;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=2;ao=2;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C524T;aa_name=p.T175I;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	26527	26527	.	+	.	ID=ID_44;Name=p.A2V;chrom_region=M;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=2;ao=2;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C5T;aa_name=p.A2V;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	del	27794	27794	.	+	.	ID=ID_45;Name=c.-99_-97delTTA;chrom_region=intergenic;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=TTTA;Variant_seq=T;nt_name=c.-99_-97delTTA;aa_name=;vcf_gene=ORF8;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	28271	28271	.	+	.	ID=ID_46;Name=c.A-3T;chrom_region=intergenic;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=A;Variant_seq=T;nt_name=c.A-3T;aa_name=;vcf_gene=N;mutation_type=;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	28297	28297	.	+	.	ID=ID_47;Name=p.N8N;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=T;Variant_seq=C;nt_name=c.T24C;aa_name=p.N8N;vcf_gene=N;mutation_type=SILENT;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
MN908947.3	.	snp	28932	28932	.	+	.	ID=ID_48;Name=p.A220V;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=4;dp=4;Reference_seq=C;Variant_seq=T;nt_name=c.C659T;aa_name=p.A220V;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.620;multi_aa_name=;multiaa_comb_mutation=;sample_size=4;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Unnamed;status=VUM;voi_designation_date=;voc_designation_date=;vum_designation_date=14-Jul-2021;
